摘要
目的:探讨化疗对合并2型糖尿病(T2DM)恶性肿瘤患者血清TGF-β1水平的影响。方法:按配对设计入选80例分为实验组(合并T2DM恶性肿瘤)40例,对照组(非合并T2DM恶性肿瘤)40例,均给予2个周期化疗,采集每个周期化疗前1天和化疗结束后第2天早晨空腹静脉血2mL,分离血清,ELISA法检测血清TGF-β1的含量。结果:实验组2个周期化疗前后血清TGF-β1的表达水平与对照组相比,差异无统计学意义(P>0.05)。实验组第1个周期化疗后血清TGF-β1含量降低,而第2个周期化疗后含量却较第2个周期化疗前升高,差异有统计学意义(P<0.05);对照组第1、2个周期化疗后血清TGF-β1含量呈持续降低趋势,差异有统计学意义(P<0.05)。结论:第1个周期化疗可促进合并/非合并T2DM恶性肿瘤患者血清TGF-β1水平下降。第2个周期化疗可促进合并T2DM恶性肿瘤患者血清TGF-β1水平升高。
Objective： To explore the effects ofchemotherapy on serum TGF-β1 expression in cancer patients with type 2 diabetes mellitus （ T2DM ）. Methods： In accordance with a matched-pair study design, 40 patients were assigned to the experimental group （ Group 1; malignant tumor with T2DM ） and 40 others were assigned to the control group （ Group 2; malignant tumor without T2DM ）. All patients underwent two cycles of chemotherapy. Two-milliliter samples of fasting venous blood were collected in the morning before and after the day of chemotherapy. Sera were separated and refrigerated at -40℃ for further testing. Enzyme-linked immunosorbent assay was used to measure changes in the level of serum TGF-β1. Results： Differences in the expression of serum TGF β-1 between Groups 1 and 2 before and after each cycle of chemotherapy were not statistically significant （ P 〉 0.05 ）. The expression of serum TGF-β1 decreased in Group 1 after the first cycle of chemotherapy; however, the serum level after the second cycle of chemotherapy increased compared with the content of serum TGF-β1 before the cycle started. The expression of serum TGF-β1 exhibited a continuous decreasing trend after both cycles of chemotherapy in Group 2, and the differences were statistically significant between them （ P 〈 0.05 ）. Conclusion： The expression level of serum TGF-β1 decreased after the first cycle of chemotherapy in both study groups, but it increased after the second cycle of chemotherapy in the experimental group.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2012年第10期715-717,727,共4页
Chinese Journal of Clinical Oncology
